FdaApplication
NDA 050630
Identifiers
- fda_app_no: NDA050630
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK AND CO INC |
| application_type | NDA |
| approval_date | 1990-12-14 |
Revenue by product
PRIMAXIN
| Period | Revenue |
|---|---|
| Q4 2023 | $39.0M* |
| Q3 2023 | $41.0M* |
| Q2 2023 | $53.0M* |
| Q1 2023 | $80.0M* |
| Q4 2022 | $54.0M* |
| Q3 2022 | $63.0M* |
| Q2 2022 | $64.0M* |
| Q1 2022 | $58.0M* |
| Q4 2021 | $65.0M* |
| Q3 2021 | $70.0M* |
| Q2 2021 | $60.0M* |
| Q1 2021 | $65.0M* |
| Q4 2020 | $62.0M* |
| Q3 2020 | $74.0M* |
| Q2 2020 | $64.0M* |
| Q1 2020 | $51.0M* |
| Q4 2019 | $66.0M* |
| Q3 2019 | $77.0M* |
| Q2 2019 | $71.0M* |
| Q1 2019 | $59.0M* |
| Q4 2018 | $53.0M* |
| Q3 2018 | $72.0M* |
| Q2 2018 | $68.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PRIMAXIN | CILASTATIN SODIUM; IMIPENEM | EQ 750MG BASE/VIAL;750MG/VIAL | POWDER;INTRAMUSCULAR |
| PRIMAXIN | CILASTATIN SODIUM; IMIPENEM | EQ 500MG BASE/VIAL;500MG/VIAL | POWDER;INTRAMUSCULAR |
2 products